Manja Friese-Hamim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Manja Friese-Hamim has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Joachim Albers
Research Unit Oncology, the healthcare business of Merck KGaA, Darmstadt, Germany
85 shared publications - Baek Kim
Department of Pediatrics, School of Medicine, Emory University, Atlanta, USA
78 shared publications - Chiara Pozzato
Institute of Pharmacology, University of Bern, 3010, Bern, Switzerland
78 shared publications - Daniel Matthias Aebersold
Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
78 shared publications - Jonas P. Koch
Department of Radiation Oncology, Inselspital Bern University Hospital, Bern, Switzerland. 1
78 shared publications - Matúš Medo
Department for BioMedical Research, University of Bern, Bern, Switzerland
78 shared publications
Latest Publications
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
GART protein expression upon MAPK and PI3K targeting: GART protein levels in untreated GTL-16 and EBC-1 cells and after MAPK (AZD6244) and PI3K (LY294002) pathways inhibition. ß Actin was used as a loading control.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
GART protein expression upon MAPK and PI3K targeting: GART protein levels in untreated GTL-16 and EBC-1 cells and after MAPK (AZD6244) and PI3K (LY294002) pathways inhibition. ß Actin was used as a loading control.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Summary of the significance analysis for the survival analyses.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Summary of the significance analysis for the survival analyses.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Basic statistics of the downloaded TCGA data.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Basic statistics of the downloaded TCGA data.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Differential abundance analysis and ion annotation matches for non-targeted metabolomics measurements.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Differential abundance analysis and ion annotation matches for non-targeted metabolomics measurements.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Supplementations with nucleosides and hypoxanthine: (A) Proliferation of GTL-16 and EBC-1 cells upon supplementation with nucleosides or hypoxanthine. (B) Apoptosis (caspase-3 activation) in GTL-16 and EBC-1 upon supplementation with nucleosides, hypoxanthine or their combination.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Supplementations with nucleosides and hypoxanthine: (A) Proliferation of GTL-16 and EBC-1 cells upon supplementation with nucleosides or hypoxanthine. (B) Apoptosis (caspase-3 activation) in GTL-16 and EBC-1 upon supplementation with nucleosides, hypoxanthine or their combination.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Basic statistics of the downloaded TCGA data.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Basic statistics of the downloaded TCGA data.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
GART protein expression upon MAPK and PI3K targeting: GART protein levels in untreated GTL-16 and EBC-1 cells and after MAPK (AZD6244) and PI3K (LY294002) pathways inhibition. ß Actin was used as a loading control.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
GART protein expression upon MAPK and PI3K targeting: GART protein levels in untreated GTL-16 and EBC-1 cells and after MAPK (AZD6244) and PI3K (LY294002) pathways inhibition. ß Actin was used as a loading control.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Summary of the significance analysis for the survival analyses.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Summary of the significance analysis for the survival analyses.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Supplementations with nucleosides and hypoxanthine: (A) Proliferation of GTL-16 and EBC-1 cells upon supplementation with nucleosides or hypoxanthine. (B) Apoptosis (caspase-3 activation) in GTL-16 and EBC-1 upon supplementation with nucleosides, hypoxanthine or their combination.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Supplementations with nucleosides and hypoxanthine: (A) Proliferation of GTL-16 and EBC-1 cells upon supplementation with nucleosides or hypoxanthine. (B) Apoptosis (caspase-3 activation) in GTL-16 and EBC-1 upon supplementation with nucleosides, hypoxanthine or their combination.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Differential abundance analysis and ion annotation matches for non-targeted metabolomics measurements.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network
Differential abundance analysis and ion annotation matches for non-targeted metabolomics measurements.